Tau protein abnormalities are key pathogenic components of Alzheimer disease and other neurodegenerative diseases. New studies in the less common primary tauopathies, including progressive supranuclear palsy, chronic traumatic encephalopathy and frontotemporal lobar degeneration have identified novel mechanisms that initiate tau pathology and biomarkers to measure disease during life.